Table 2 Intensive care management and outcomes of patients with severe SARS-CoV-2 infection (n = 158) during their intensive care unit stay according to the SARS-CoV-2 infecting “sublineage groups” (BA.2 vs BA.4/BA.5 vs BQ.1.1 group)
Data available | All patients | BA.2 | BA.4/BA.5 | BQ.1.1 group | p-value | |
|---|---|---|---|---|---|---|
N = 158 | N = 50 | N = 61 | N = 47 | |||
Invasive MV | 158 | 49 (31.2) | 16 (32.0) | 20 (33.3) | 13 (37.7) | 0.812 |
Prone positioning | 158 | 28 (19.7) | 11 (23.9) | 11 (20.0) | 6 (14.6) | 0.553 |
MV duration, days | 158 | 9 (3;18) | 12 (5;25) | 9 (2;17) | 4 (2;14) | 0.213 |
Live-ventilator free days at day 28 | 158 | 28 (0;28) | 28 (0;28) | 28 (0;28) | 28 (6;28) | 0.823 |
ECMO support | 158 | 2 (1.3) | 1 (2.0) | 1 (1.7) | 0 (0) | 1.000 |
Vasopressor support | 158 | 46 (29.5) | 13 (26.0) | 19 (31.7) | 14 (30.4) | 0.797 |
Renal replacement therapy | 158 | 16 (10.2) | 4 (8.0) | 7 (11.7) | 5 (10.6) | 0.847 |
Ventilator-acquired pneumonia (among IMV)a | 49 | 20 (40.8) | 7 (43.8) | 8 (40.0) | 5 (38.5) | 1.000 |
CAPA | 158 | 8 (5.1) | 5 (10.0) | 2 (3.3) | 1 (2.2) | 0.160 |
Dexamethasone | 158 | 113 (72.0) | 38 (76.0) | 42 (70.0) | 33 (70.2) | 0.773 |
Other steroids | 158 | 0 | 0 | 0 | 0 | – |
Tocilizumab | 158 | 30 (19.4) | 14 (28.0) | 11 (18.6) | 5 (10.9) | 0.104 |
Nirmatrelvir-ritonavir | 157 | 14 (8.9) | 2 (4.0) | 10 (16.7) | 2 (4.3) | 0.028 |
Monoclonal antibodies | 158 | 18 (13.0) | 10 (20.8) | 2 (3.8) | 6 (15.8) | 0.022 |
Casirivimab-Imdevimab | 158 | 1 (5.6) | 0 (0) | 0 (0) | 6 (15.8) | 0.444 |
Tixagevimab-Cilgavimab | 158 | 17 (94.4) | 10 (100.0) | 2 (100.0) | 5 (3.3) | 0.444 |
Sotrovimab | 158 | 0 | 0 | 0 | 0 | – |
Duration of ICU stay, days | 158 | |||||
All patients | 158 | 8 (4; 16) | 11 (5; 22) | 7 (3; 15) | 6 (4; 12) | 0.048 |
Survivors only | 121 | 7 (3; 16) | 9 (5; 22) | 6 (3; 14) | 6 (4; 15) | 0.069 |
Day-28 mortality | 158 | 37 (23.7) | 11 (22.0) | 16 (26.7) | 10 (21.7) | 0.791 |